GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (HAM:RGO) » Definitions » Cyclically Adjusted PS Ratio

Regeneron Pharmaceuticals (HAM:RGO) Cyclically Adjusted PS Ratio : 11.73 (As of May. 17, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Regeneron Pharmaceuticals Cyclically Adjusted PS Ratio?

As of today (2024-05-17), Regeneron Pharmaceuticals's current share price is €898.60. Regeneron Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €76.62. Regeneron Pharmaceuticals's Cyclically Adjusted PS Ratio for today is 11.73.

The historical rank and industry rank for Regeneron Pharmaceuticals's Cyclically Adjusted PS Ratio or its related term are showing as below:

HAM:RGO' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 9.17   Med: 16.04   Max: 62.51
Current: 11.68

During the past years, Regeneron Pharmaceuticals's highest Cyclically Adjusted PS Ratio was 62.51. The lowest was 9.17. And the median was 16.04.

HAM:RGO's Cyclically Adjusted PS Ratio is ranked worse than
74.07% of 513 companies
in the Biotechnology industry
Industry Median: 5.51 vs HAM:RGO: 11.68

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Regeneron Pharmaceuticals's adjusted revenue per share data for the three months ended in Mar. 2024 was €25.138. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €76.62 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Regeneron Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Regeneron Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.99 12.54 11.43 10.59 11.06

Regeneron Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.49 9.64 10.62 11.06 11.62

Competitive Comparison of Regeneron Pharmaceuticals's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Regeneron Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regeneron Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Regeneron Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



Regeneron Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Regeneron Pharmaceuticals's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=898.60/76.62
=11.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regeneron Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Regeneron Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=25.138/131.7762*131.7762
=25.138

Current CPI (Mar. 2024) = 131.7762.

Regeneron Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 4.335 100.560 5.681
201409 4.796 100.428 6.293
201412 5.706 99.070 7.590
201503 7.016 99.621 9.281
201506 7.720 100.684 10.104
201509 8.741 100.392 11.474
201512 8.728 99.792 11.525
201603 9.440 100.470 12.381
201606 9.285 101.688 12.032
201609 9.334 101.861 12.075
201612 10.069 101.863 13.026
201703 10.714 102.862 13.726
201706 11.266 103.349 14.365
201709 10.759 104.136 13.615
201712 11.565 104.011 14.652
201803 10.669 105.290 13.353
201806 12.021 106.317 14.900
201809 12.386 106.507 15.325
201812 2.776 105.998 3.451
201903 10.517 107.251 12.922
201906 12.185 108.070 14.858
201909 13.864 108.329 16.865
201912 14.673 108.420 17.834
202003 14.375 108.902 17.394
202006 14.702 108.767 17.812
202009 17.099 109.815 20.519
202012 17.766 109.897 21.303
202103 19.223 111.754 22.667
202106 38.492 114.631 44.249
202109 25.767 115.734 29.339
202112 38.644 117.630 43.292
202203 23.805 121.301 25.861
202206 23.710 125.017 24.992
202209 26.290 125.227 27.665
202212 28.249 125.222 29.728
202303 25.907 127.348 26.808
202306 25.592 128.729 26.198
202309 27.785 129.860 28.195
202312 27.698 129.419 28.202
202403 25.138 131.776 25.138

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Regeneron Pharmaceuticals  (HAM:RGO) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Regeneron Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Regeneron Pharmaceuticals (HAM:RGO) Business Description

Traded in Other Exchanges
Address
777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).

Regeneron Pharmaceuticals (HAM:RGO) Headlines

No Headlines